Evidence map›Paper›PMID 25110576›Full record

ArticleF1000Research2013

Functional characterization of Candida albicans Hos2 histone deacetylase.

G Karthikeyan, Maneesh Paul-Satyaseela, Nachiappan Dhatchana Moorthy, Radha Gopalaswamy, Shridhar Narayanan

Open access · goldAbstract read
In one paragraph

Article in F1000Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Chromatin Structure and Drug Resistance inJournal of fungi (Basel, Switzerland) · 2020
    Review
  2. Review
  3. Review
  4. Novel hydroxamates potentiatedJournal of natural science, biology, and medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

G KarthikeyanDrug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Chennai, 600 119, India.
Maneesh Paul-SatyaseelaDrug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Chennai, 600 119, India ; Current address: Samrud Foundation for Health & Research, Bangalore, 560106, India.
Nachiappan Dhatchana MoorthyDrug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Chennai, 600 119, India.
Radha GopalaswamyDrug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Chennai, 600 119, India.
Shridhar NarayananDrug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Chennai, 600 119, India ; Current address: AstraZeneca India Pvt. Ltd, Bengaluru, 560024, India.
Orchid Pharma (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Candida albicans is a mucosal commensal organism capable of causing superficial (oral and vaginal thrush) infections in immune normal hosts, but is a major pathogen causing systemic and mucosal infections in immunocompromised individuals. Azoles have been very effective anti-fungal agents and the mainstay in treating opportunistic mold and yeast infections. Azole resistant strains have emerged compromising the utility of this class of drugs. It has been shown that azole resistance can be reversed by the co-administration of a histone deacetylase (HDAC) inhibitor, suggesting that resistance is mediated by epigenetic mechanisms possibly involving Hos2, a fungal deacetylase. We report here the cloning and functional characterization of  HOS2 (High Osmolarity  Sensitive) , a gene coding for fungal histone deacetylase from  C. albicans. Inhibition studies showed that Hos2 is susceptible to pan inhibitors such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), but is not inhibited by class I inhibitors such as MS-275. This  in  vitro enzymatic assay, which is amenable to high throughput could be used for screening potent fungal Hos2 inhibitors that could be a potential anti-fungal adjuvant. Purified Hos2 protein consistently deacetylated tubulins, rather than histones from TSA-treated cells. Hos2 has been reported to be a putative NAD+ dependent histone deacetylase, a feature of sirtuins. We assayed for sirtuin activation with resveratrol and purified Hos2 protein and did not find any sirtuin activity.

Identifiers

PMID25110576
PMCPMC4111124
OpenAlexW2095182224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.